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Abstract Objective: More than 11% of the Caucasian
population are heterozygous or homozygous carriers
of thiopurine S-methyltransferase (TPMT) mutants
and are at risk for toxic side eﬀects when treated with
thiopurine drugs. Therefore, screening for TPMT
polymorphisms in a patient prior to prescribing these
agents is recommended. The goal of this study was to
determine a cut-oﬀ concentration of the TPMT
activity assay beyond which genotyping of the TPMT
gene should be performed.
Methods: The TPMT activity of 240 unrelated Caucasian
subjects was measured using high-performance liquid
chromatography. Genotyping for the most frequent
allelic variants, TPMT*2, *3A, *3B, *3C and *7 was
performed by LightCycler technology and sequencing.
Results: The inter-individual TPMT activity showed a
range from 23 nmol MTG/g*Hb*h)1 to 97 nmol MTG/
g*Hb*h)1 with a median of 56 nmol MTG/g*Hb*h)1.
Using a cut-oﬀ concentration of 45.5 nmol MTG/
g*Hb*h)1, a test sensitivity of 100% and a speciﬁcity of
89% were reached for heterozygous carriers of a TPMT
mutation. We identiﬁed 1 carrier of TPMT*2, 14 carriers
of TPMT*3A and 3 carriers of TPMT*3C, resulting in a
TPMT heterozygosity prevalence of 7.5%.
Conclusions: This study deﬁnes the cut-oﬀ value for the
TPMT phenotyping assay at 45.5 nmol/g*Hb*h)1, be-
yond which additional genotyping elucidates the indi-
vidual risk for drug therapy. Using this cut-oﬀ
concentration, the number of genotyping assays could be
reduced by about 60%.
Keywords Thiopurine methyltransferase Æ Thiopurine
drugs Æ Single nucleotide polymorphisms
Introduction
Thiopurine S-methyltransferase (TPMT; EC 2.2.2.67)
is a cytosolic enzyme, which catalyzes the S-methyla-
tion of widely used immunosuppressive but also
cytotoxic thiopurine drugs, such as 6-thioguanine,
6-mercaptopurine and azathioprine [1]. The in vivo
activity of this enzyme is characterised by inter-indi-
vidual and inter-ethnic variability caused by genetic
polymorphisms in the TPMT gene. The frequency
distribution of TPMT activity in Caucasian population
studies is trimodal: 1 in 300 subjects has undetectable
activity, 11% have intermediate activity and 89%
inherit high enzyme activity [2]. The gene that codes
for TPMT has been localised to chromosome 6
(6p22.3). Various TPMT alleles, carrying a point
mutation or a combination of mutations in the ten
exons and nine introns, as well as in the 5¢-ﬂanking
promoter region, have been associated with deﬁcient,
intermediate or high activity [3, 4, 5, 6, 7]. As a
consequence, individuals greatly diﬀer in the detoxiﬁ-
cation of thiopurine drugs to 6-methylmercaptopurine
and, thus, in the occurrence of side eﬀects or reduced
therapeutic eﬃcacy. TPMT polymorphisms have been
linked with severe and potentially fatal myelosup-
pression in deﬁcient metabolisers and rejection of
transplanted organs in high metabolisers [8, 9, 10].
Therefore, phenotyping and/or genotyping tests for
TPMT prior to thiopurine therapy should become
routine practice to avoid severe haematotoxicity in
TPMT-deﬁcient patients and to lower the incidence of
haematological side eﬀects in heterozygous individuals.
But it has to be considered that not every risk can be
eliminated by the analysis of the TPMT gene. It is
well known that during an established thiopurine drug
therapy in some wild-type patients diﬀerent side eﬀects
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can occur, which are independent of TPMT poly-
morphisms, such as pancreatitis, hepatotoxicity, pan-
cytopenia, nausea, vomiting or abdominal pain [11,
12, 13]. Nevertheless, congenital patients who are at
risk can be detected, and drug-induced toxicity can be
prevented from the beginning of the therapy.
TPMT molecular pharmacogenetic studies resulted
in the discovery of a series of variant alleles (single
nucleotide polymorphisms) associated with signiﬁ-
cantly decreased levels of TPMT activity. The most
common of these variant alleles in Caucasian popu-
lations, TPMT*3A, is characterised by the combined
appearance of two single nucleotide polymorphisms
(SNPs) in exon 7 (G460A) and exon 10 (A719G),
which result in Ala ﬁ Thr and Tyr ﬁ Cys substitu-
tions, respectively. TPMT*3B (G460A) and the
TPMT*3C (A719G) alleles are caused by the sole
presence of the exon 7 and exon 10 mutations,
respectively [3, 5, 14]. For TPMT*2, a G238C muta-
tion in exon 5 causes an Ala ﬁ Pro substitution [7].
Further, a polymorphic tandem repeat was identiﬁed
within a GC-rich area in the 5¢-ﬂanking region of the
TPMT gene. The most common alleles were those
with four and ﬁve 17-bp or 18-bp repeats. An inverse
relationship was found: the larger the number of
repeats, the lower the activity. As a conclusion, a
modulation of TPMT activity by the variable number
of tandem repeats was discussed [15]. Various detec-
tion possibilities of TPMT genotyping assays have
been published, e.g. polymerase chain reaction-single-
strand conformation polymorphism (PCR-SSCP) [16],
denaturing high-performance liquid chromatography
(HPLC) [17], sequencing [6] and melting-curve analysis
[18].
Phenotyping represents a possibility to test the
metabolic capacity of TPMT. At the beginning, the
enzyme activity was measured by a radiochemical
assay [19]; more recently, HPLC methods have been
published [20, 21, 22]. All these methods are based on
the in vitro conversion of 6-mercaptopurine to
6-methylmercaptopurine or 6-thioguanine to 6-meth-
ylthioguanine, using S-adenosyl-L-methionine as the
methyl donor. The product of the enzymatic reaction
is extracted by liquid–liquid or solid-phase extraction
and is measured by HPLC with ultraviolet (UV) or
ﬂuorescence detection.
The general advantage of phenotyping is a reliable
detection of an individual’s enzyme activity at less costs
per analysis compared with genotyping analysis, which
includes laborious DNA extraction, time-consuming
thermocycling programs and interpretation of agarose
gels or chromatograms. Overall, for the implementation,
the infrastructure for the phenotyping assay, such as
HPLC-UV systems, is more often available in labora-
tories than, for example, realtime thermocycling
systems, such as LightCycler technology. We report a
phenotype–genotype comparison of the TPMT enzyme
and develop a new screening strategy for patients prior
to taking thiopurine drugs.
Materials and methods
Reagents and chemicals
Ammonium formate and sodium 1-hexansulfonate monohydrate
were supplied by Fluka (Buchs, Switzerland). Methanol and dic-
hlormethane were obtained from Scharlau (Barcelona, Spain),
acetonitrile from Biosolve (Valkenswaard, Netherlands) and
potassium dihydrogenphosphate, 2-propanol and acetic acid from
Merck (Darmstadt, Germany). Acetonitrile and methanol were of
HPLC grade; all other chemicals were of analytical grade.
6-Methylthioguanine, 6-thioguanine and S-adenosyl-L-methionine
were purchased from Sigma-Aldrich (Steinheim, Germany).
Oligonucleotides
Primers for sequencing TPMT *3C and *7 (exon 10) were designed
with the Oligo 4.0 software, purchased from Microsynth (Balgach,
Switzerland). The LightCycler primers and probes for TPMT *2
and TPMT *3B were synthesised by TibMolbiol (Berlin, Ger-
many). The hybridisation probes were labelled with LCRed640,
Cy5.5 or FL (ﬂuorescein) with a phosphate molecule at the 3¢ end.
Subjects
Venous blood from 102 unrelated healthy volunteers and 138
patients with inﬂammatory bowel disease from the University
Hospital Zurich was collected in blood collection tubes containing
ethylenediaminetetraacetate. The local ethics committee approved
this study, and an informed consent was obtained from all blood
donors. DNA was isolated with the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany).
Phenotyping
The TPMT activity assay was performed according to Kroplin [22]
with minor modiﬁcations. The haemoglobin content (Hb) of the
red blood cell lysate was measured by a Microcellcounter F500
(Sysmex, Hamburg, Germany). The sample volume of each patient
consisted of 50 ll red blood cell lysate and was equal to the pub-
lished method, whereas the extraction of the product was made
with dichlormethane/2-propanol (90/10; v/v) instead of chloro-
form/2-propanol (90/10; v/v). The HPLC system consisted of a
9010 pump, a 9100 autosampler and a 9050 UV-VIS detector
(Varian, Sunnyvale, CA, USA). The detector was set at 290 nm and
the injection volume was 100 ll. 6-Thioguanine and 6-methyl-
thioguanine were separated using a reversed-phase C18 column
Phenomenex Aqua (250·4.6 mm, 5 l, 125A, Torrance, California,
USA). Eluent A consisted of ammonium acetate buﬀer 5 mM/
pH 3, methanol, acetonitrile (95/2.5/2.5; v/v/v) with 0.2%
hexanesulfonic acid; eluent B consisted of ammonium acetate
buﬀer 5 mM/pH 3, methanol, acetonitrile (5/75/20; v/v/v). The
mobile phase was mixed in a gradient system starting with 100% A,
after 5 min changing to 50% A, 50% B during 5 min, which was
then maintained for 10 min. The ﬂow rate was 1.0 ml/min.
Genotyping
The genotyping of TPMT*3C (A719G) was carried out using PCR,
followed by Big Dye Terminator Cycle Sequencing Ready Reaction
Kit (Perkin Elmer, Applied Biosystems, Foster City, CA, USA),
according to the manufacturer’s instructions. For TPMT *3C, the
primers were L1 5¢ATCTTTCACATCATAATCTCCTCTCCAA
and U1 5¢ AATCCCTGATGTCATTCTTCATAGTATT,
according to Otterness et al. [6] with minor modiﬁcations. The PCR
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ampliﬁcations were performed in a thermal cycler (Perkin-Elmer,
Gene Amp PCR System 9600). The 50 ll reaction volume included
5 ll genomic DNA (ca 50 ng/ll) as template, 1.0 ll of each primer
*3C L1 and *3C U1 (10 mM), 1.0 ll of dNTP mixture (10 mM),
5.0 ll 10· buﬀer II, 8.0 ll of magnesium chloride (25 mM), 0.4 ll
Gold Taq (5 U/ll) and 28.6 ll of water. The following cycling
conditions were used: 10 min at 94 C, 40 cycles of 94 C for 30 s,
63 C for 30 s and 72 C for 60 s and a ﬁnal extension of 7 min at
72 C. The 10 ll sequencing reaction volume contained 4.0 ll of Big
Dye Reaction Mix, 1.0 ll *3CU1 (10 mM) and 5.0 ll of puriﬁed
ampliﬁcation product. The sequencing reaction conditions involved
45 s at 94 C, 25 cycles of 10 s at 96 C, 5 s at 55 C and 90 s of 60 C.
Sequencing analysis was carried out on an ABI Prism Model 310
DNA sequencer (Perkin Elmer, Applied Biosystems).
The LightCycler PCR assays for TPMT* 2 and TPMT* 3B
were applied from Schutz et al. [18]. The primers and probes for
TPMT*2 (exon 5) were cctgcatgttctttgaaaccctatgaa (intron4for),
gcttgagtacagagaggctttgacctc (exon5rev), LCR-ggtctgcaaacctgcataa-
PHO (tpmt *2) and CY-atttccacaccaactacactgtgtc-FL (anchor) and
for TPMT*3B (exon 7) ctccacacccaggtccacacatt (intron6for), gta-
tagtatactaaaaaattaagacagctaaac (exon7rev), ggcaactaatgctcctctat-
catcc-FL (tpmt *3b) and CY-atcatgtcaaatttgccaatatttgtcctaccag-
PHO (anchor). The assay conditions were identical to Schutz et al.
[18].
Statistical analysis
Descriptive statistics and multiple correlations were calculated
using Excel 97 (Microsoft, USA) and StatView (SAS, Cary, NC,
USA). Median and mean values of TPMT activity were compared
using nonparametric statistics and t-tests, respectively. A P value of
less than 0.05 was considered to be statistically signiﬁcant. Re-
ceiver-operating-characteristics (ROC analysis) were applied for
the calculation of the cut-oﬀ concentration for the TPMT pheno-
typing assay. The chi-square test was used to compare the fre-
quencies of TPMT phenotypes between subgroups. For diagnostic
signiﬁcance analysis, calculations were made as follows: test sen-
sitivity=RP/(RP+FN), test speciﬁcity=RN/(RN+FP), test eﬃ-
ciency=(RP+RN)/(RP+FN+FP+RN) and positive predictive
value=RP/(RP+FP) (abbreviations: RP right positive, FP false
positive, RN right negative, FN false negative).
Results
Genotyping was performed for the ﬁve most frequent
SNPs: TPMT *2, *3A, *3B, *3C and *7. The total fre-
quency of heterozygous subjects in our collective was
7.5%. The frequencies of the TPMT *2, *3A and *3C
alleles were 0.4%, 5.8% and 1.3%, respectively
(Table 1).
A typical chromatogram of the TPMT phenotyping
assay is shown in Fig. 1. The retention time for
6-methylthioguanine was about 13.7 min.
Minor modiﬁcations of the phenotyping assay con-
ditions, such as the extraction step and the UV detection
instead of the ﬂuorescence detection resulted in an in-
crease of the median TPMT activity of 44% (56 nmol
versus 38.8 nmol MTG/g*Hb*h)1) compared with
Kroplin et al. [22]. The inter-individual TPMT enzyme
activity ranged from 23 nmol MTG/g*Hb*h)1 to
97 nmol MTG/g*Hb*h)1.
Based on the genotyping results, mean values of
TPMT activity were calculated for wild-type and het-
erozygous subjects, respectively (Table 2). Signiﬁcant
TPMT activity diﬀerences between the two groups re-
sulted in a P value <0.0001. The normal distribution of
TPMT activity among wild-type and heterozygous car-
riers is depicted in Fig. 2. The analysis of the healthy
controls and the group taking thiopurine drugs dem-
onstrated no signiﬁcant diﬀerences in the mean of
TPMT activity between the two collectives; conse-
quently, no enzyme-induction phenomena could be
observed. Additionally, gender diﬀerences could not be
detected.
The correlation between phenotype and genotype
according to the SNPs is demonstrated in Fig. 3. As
expected, samples with one mutated allele had a lower
TPMT activity than samples with two wild-type alleles,
but a well-deﬁned cut-oﬀ concentration could not be set.
The optimal cut-oﬀ activity for the TPMT phenotype
assay to predict a heterozygous carrier was chosen by
ROC analysis (Fig. 4), with the aim to include all het-
erozygous samples. The calculated cut-oﬀ activity was
45.5 nmol MTG/g*Hb*h)1 with a test sensitivity of
100% and a speciﬁcity of 89%. The test eﬃciency was
90% and the positive predictive value of a TPMT
activity below the cut-oﬀ amounted to 42%.
Discussion
The genetic TPMT polymorphism represents a striking
example of the potential clinical importance of phar-
macogenetic variation of a drug-metabolising enzyme
[23]. The incidence of TPMT mutations for the Cauca-
sian population is reported to be 0.3% for homozygous,
11% for heterozygous and 89% for wild-type carriers
[2]. Homozygous mutated individuals are at increased
risk for potentially life-threatening toxicity when
exposed to standard doses of thiopurine drugs, while
Table 1 Frequencies of thiopurine S-methyltransferase (TPMT) mutations analysed in a Swiss population sample
TPMT genotype Exon Nucleotide substitution Amino acid exchange No. of subjects Observed frequency [%]
TPMT *1/*1 Wild type 222 92.5
TPMT *1/*2 5 G238C Ala80Pro 1 0.4
TPMT *1/*3A 7/10 G460A/A719G Ala154Thr/Tyr240Cys 14 5.8
TPMT *1/*3B 7 G460A Ala154Thr 0 0.0
TPMT *1/*3C 10 A719G Tyr240Cys 3 1.3
TPMT *1/*7 10 T681G His227Glu 0 0.0
Total heterozygous 18 7.5
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heterozygous carriers have to start the immunosuppres-
sive therapy with 50–60% of the recommended dose [24].
The molecular basis of TPMT deﬁciency is well
understood; TPMT *2, *3A, *3B, *3C and *7 are the
most common variants and account for 80% of all
possible mutations [4]. Rare variants, such as *3D, *4,
*5 and *6 were omitted in this genotyping study. The
incidence of these mutations was 0% in a collective of
191 subjects [25]. Furthermore, promoter polymor-
phisms were ignored because of their minor eﬀect on the
modulation of TPMT activity compared with SNPs in
the open reading frame [15].
As the consequences of individualised thiopurine
drug therapy would be of potential beneﬁt for a single
patient, we compared the TPMT activity, as determined
by a non-radiochemical assay, with the TPMT genotype,
assessed using a realtime PCR-based technique and
sequencing.
In our cohort, TPMT*2, *3A, *3B, *3C and *7
mutations had similar prevalences (7.5%), as seen in
reference populations [2, 4, 6, 25, 26]. The heterozygosity
rate varies in these studies between 7.4% and 13.5%.
The higher prevalence of mutated subjects in these
clinical trials can be attributed to the preselection of the
subjects, such as leukaemia patients with toxicity under
thiopurine drugs [27].
In order to determine the distribution of TPMT
activity, blood samples from randomly collected healthy
donors were obtained and compared with the levels
measured in samples from patients undergoing a thiop-
urine drug therapy. Apart from the mean diﬀerences
between wild-type and heterozygous carriers, no other
inﬂuencing factors could be observed. The trimodale
enzyme activity distribution could not be shown thus
far, due to the absence of a homozygous-mutated indi-
vidual, who is deﬁcient in TPMT activity. The preva-
lence of 0.3% lets assume that our collective of 240
individuals has to be enlarged for this purpose. The
TPMT activity distribution between heterozygous car-
riers and wild-type subjects led to the deﬁnition of a cut-
oﬀ concentration (45.5 nmol/g*Hb*h)1) beyond which
genotyping has to be performed. The cut-oﬀ of the
phenotyping assay was set at an activity with a proba-
bility of 100% to detect a heterozygous subject. The
sensitivity and speciﬁcity analysis was optimised to de-
tect all heterozygous samples so that the test can be used
as a screening assay for genotyping. The speciﬁcity ac-
counts for 89%, which can be accepted, as the number
of genotyping assays is reduced to a reasonable number.
Phenotype/genotype discrepancies, such as false posi-
tives that result in TPMT activity measurements (i.e. low
TPMT activity) despite wild-type genotype, were ex-
plained thus far by missed SNPs in the open reading
frame, the variable number of tandem repeats in the
promotor region [16] or patients’ age [28] and renal
function, as well as drug interactions [29]. The analysis
of our patients with wild-type genotype and an activity
beyond the deﬁned cut-oﬀ concentration resulted in
subjects of all age, who ranged from 17 years to
78 years. Further, the phenomenon was observed in
healthy controls (n=8), as well in patients under thi-
opurine drugs (n=17). No correlation was found be-
tween renal function, measured by creatinine clearance,
and TPMT activity. Our observation showed that pa-
tients who had a TPMT activity below the cut-oﬀ con-
centration, but without a mutation on the TPMT gene,
tolerated a thiopurine drug therapy with standard doses.
The aim of the study was not to detect each possible
mutation on the TPMT gene, but to extract those
Fig. 1 Chromatogram of the thiopurine S-methyltransferase phe-
notyping assay: the educt 6-thioguanine is detected at Rt=12.1 min
and the product 6-methylthioguanine at Rt=13.7 min
Table 2 Thiopurine S-methyltransferase (TPMT) genotype compared to TPMT activity means according to sex and collective
Genotype Collective No. of subjects Sex No. of subjects Mean±SD (nmol MTG/g*Hb*h)1)
Wild type Healthy 95 Male 59 58.8±9.8
Female 36 55.5±10.5
Under thiopurine drug therapy 127 Male 61 59.3±12.4
Female 66 57.8±12.1
222 58.1±11.4*
Heterozygous Healthy 7 Male 5 31.1±5.1
Female 2 32.1; 39.8
Under thiopurine drug therapy 11 Male 4 39.8±7.0
Female 7 34.9±5.6
18 35.4±6.1*
*P<0.0001
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patients supposed to be at risk for toxicity during intake
of thiopurine drugs. The number of genotyping assays
could be reduced to 40% of the samples, which is cost
eﬀective and timesaving. By applying our recommended
phenotyping method, possible savings amounted to be-
tween 40% and 50% of the overall costs, depending on
the standard rates of each hospital. In addition, it al-
lowed an earlier start of therapy for most of the patients,
as they are wild type and have a low risk for toxicity
problems under thiopurine drugs.
In conclusion, we report a screening procedure for
patients prior or subsequent to initiation of thiopurine
drug treatment.With this new combined concept, patients
can be tested rapidly for TPMT mutations, and drug
therapy can be started at individually chosen dosages.
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